Alexion Pharmaceuticals, Inc. (ALXN) 10-K Annual Report February 2019


•	U.S. launch underway for ULTOMIRIS^TM (ravulizumab-cwvz) in adults with paroxysmal nocturnal hemoglobinuria (PNH); EU and Japanese applications under review


•	Filed U.S. and EU submissions for SOLIRIS in neuromyelitis optica spectrum disorder (NMOSD) and on track to file in Japan later in 2019


•	Announced collaboration with Caelum Biosciences

BOSTON, February 4, 2019- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the fourth quarter and full year of 2018. Total revenues for the full year of 2018 were $4,131.2 million, a 16 percent increase compared to 2017. The positive impact of foreign currency on total revenues year-over-year was less than one percent, or $5.9 million, inclusive of hedging activities. On a GAAP basis, diluted earnings per share (EPS) for the full year of 2018 was $0.35, an 82 percent decrease versus the prior year, inclusive of $1,183.0 million of expense related to the value of the in-process research and development assets acquired in 2018. Non-GAAP diluted EPS for the full year of 2018 was $7.92, a 35 percent increase versus the prior year.

Total revenues in the fourth quarter were $1,128.8 million, a 24 percent increase compared to the same period in 2017. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $5.5 million, inclusive of hedging activities. On a GAAP basis, diluted EPS in the quarter was $(0.20), a 254 percent decrease versus the prior year, inclusive of $379.3 million of expense related to the value of the in-process research and development asset acquired in connection with our acquisition of Syntimmune. Non-GAAP diluted EPS for the fourth quarter of 2018 was $2.14, a 45 percent increase versus the fourth quarter of 2017.

"2018 was a transformational year for Alexion. I am proud of our many accomplishments, including entering rare neurology and making SOLIRIS for gMG Alexion's best launch ever, completing the Phase 3 program and launching ULTOMIRIS for PNH in the U.S., delivering groundbreaking Phase 3 data and submitting regulatory filings for SOLIRIS in NMOSD and rebuilding our pipeline through disciplined business development, all while continuing to grow our base business," said Ludwig Hantson, Ph.D., Chief

The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Monday, February 4, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/899866/000089986619000010/alxn10k12312018.htm

View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Alexion Pharmaceuticals, Inc..

Continue

Assess how Alexion Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Alexion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Alexion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 21.1: Subsidiaries Of Alexion Pharmaceuticals, Inc.

Exhibit 23.1: Consent Of Pricewaterhousecoopers Llp

Exhibit 31.1: Certification Of Ceo Pursuant To Section 302

Exhibit 31.2: Certification Of Cfo Pursuant To Section 302

Exhibit 32.1: Certification Of Ceo Pursuant To Section 906

Exhibit 32.2: Certification Of Cfo Pursuant To Section 906

Ticker: ALXN
CIK: 899866
Form Type: 10-K Annual Report
Accession Number: 0000899866-19-000010
Submitted to the SEC: Wed Feb 06 2019 9:03:21 AM EST
Accepted by the SEC: Wed Feb 06 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/alxn/0000899866-19-000010.htm

Alexion Pharmaceuticals, Inc. (ALXN) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

SEC Filings

ALXN Valuations

ALXN Annual Reports

ALXN Quarterly Reports

ALXN Corporate News

ALXN Merger Prospectus